9 results about "Iron Chelator" patented technology

The invention discloses application of an iron chelating agent in treatment of HSV-1 and VSV virus infection. By constructing a mouse model infected by HSV-1 and VSV viruses, it is verified that the iron chelating agent can significantly promote activation of an I-type interferon signal channel of a host after virus infection; virus replication in various tissues can be inhibited, and secretion of antiviral cell factors can be promoted; tissue inflammation damage caused by virus infection can be relieved; the immunopotentiator shows a consistent immunopotentiation effect in mouse and human immune cells; the iron chelating agent is selected from any one or a combination of more of deferoxamine mesylate, deferiprone and ciclopirox. The iron chelating agent provided by the invention does not depend on virus TK / DNApol, overcomes the defect of high drug resistance of traditional HSV-1 and VSV virus treatment drugs to a certain extent, and has good clinical application prospects and application values.

The present invention relates to products and compositions and their uses. In particular, the invention relates to nucleic acid products that interfere with or inhibit the expression of the TMPRSS6 gene in combination with one or more iron chelators and possibly other active agents, as well as to therapeutic uses such as the treatment of hemochromatosis, porphyria, and blood disorders such as beta-thalassemia, sickle cell anemia, and transfusion iron overload or myelodysplastic syndrome, as well as infections and mortality not related to relapses associated with bone marrow transplantation.

The invention generally concerns a CNS-targeting non-systemic formulation for regulating dopamine and / or serotonin levels in the central nervous system (CNS).

The application discloses a method for enhancing the sensitivity of Paecilomyces fungi to ultraviolet radiation, and belongs to the technical field of biology. Paecilomyces Based on the discovery that the biosynthesis of the tough core component pyridine dicarboxylic acid (DPA) of Paecilomyces fungi spores depends on iron-mediated enzyme activity, free iron ions are effectively stored and DPA synthesis is inhibited by applying a specific concentration of iron chelator, so that the sensitivity of Paecilomyces fungi spores to ultraviolet (UV-A and UV-B) radiation is significantly enhanced. Paecilomyces The application provides a low-cost, efficient and environment-friendly fungal control strategy, and has important application value in the fields of food safety, agriculture and industrial sterilization.

The present invention relates to a pharmaceutical dosage form comprising a drug with rapid absorption in the intestinal tract, which drug is absorbed in the distal intestinal tract, including the colon, and for which a pulsed release is necessary to avoid the potential toxicity of sustained absorption of the drug, and a method of preparing the pharmaceutical composition. In particular, the present invention relates to a dosage form comprising a formulation in the form of small coated units to deliver an active ingredient after oral administration for a predetermined period of time. In a preferred embodiment, the drug is an iron chelating agent deferiprone.

The application discloses a controllable release gallium-iron chelator composite nanohydrogel and a preparation method and application thereof. The nanohydrogel is formed by compounding gallium ions, iron chelators and a suitable polymer carrier, and can realize time and space controllable release. The nanohydrogel can first deplete the available iron of pathogens in an infection or inflammation microenvironment, induce the iron starvation response of the pathogens, and then slowly release gallium ions to simulate the role of iron, enter the pathogen cells and interfere with the iron-dependent metabolism, so as to synergistically play the roles of anti-infection and protection of host cells. The nanohydrogel can still maintain antibacterial activity in a high iron environment of pathogens through a double iron capture mechanism, and can inhibit iron-dependent cell death (such as ferroptosis) and inflammation cascade reaction of the host. The nanohydrogel has good biocompatibility, organ targeting and controllable release characteristics, can be prepared into a local drug preparation or a systemic delivery preparation, is suitable for prevention and / or treatment of diseases related to fungal or bacterial infection, and has a significant application prospect.

The present application relates to a method for improving the accuracy of in vivo cell tracking using iron chelators, comprising the following steps: S1, preparing drug materials; S2, preparing animals and cells: preparing bone marrow cells, S3, removing free iron chelators in vivo 89 Zr and 68 Ga, S4, radiolabeling mesenchymal stem cells and bone marrow cells; S5, performing Micro-PET imaging: S6, performing Micro-PET imaging data processing and analysis: S7, in vitro biodistribution; S8, performing pharmacokinetic studies; S9, extracting hAlu genomic DNA and performing qPCR detection; S10, establishing a standard curve of cell number and cycle threshold; S11, performing absorbed dose estimation; S12, performing in vitro cell experiments; S13, final statistical analysis. The present application provides a method for improving the accuracy of in vivo cell tracking using iron chelators, which realizes the effect of removing free radioactive metal ions in vivo using iron chelators, and ensures the accuracy of in vivo tracking labeled cells.

The application discloses an iron chelator, a preparation method thereof and application thereof in preparing a medicine for improving iron overload, and belongs to the technical field of organic synthesis. The iron chelator is a compound shown in formula (I), stereoisomers, tautomers, crystalline hydrates, solvates, prodrugs or pharmaceutically acceptable salts of the iron chelator, wherein R is a substituted or unsubstituted phenyl or a substituted or unsubstituted furanyl, the substituent of the phenyl is an alkyl or an alkoxy, and the substituent of the furanyl is an alkyl; R1 is H or halogen; R2 is H, a carboxyl or a trihalomethyl; and R3 is H, a carboxyl or a carboxylate. The iron chelator has an iron ion removing effect in two kinds of cells, is oral and small-dose, and provides technical support for clinical application of improving iron overload of patients with red blood cell diseases caused by repeated blood transfusion.